The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Abstract
Purpose: The epidermal growth factor receptor (EGFR) is a mediator of squamous cell carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active, selective EGFR tyrosine kinase inhibitor. This phase II study sought to explore the activity, toxicity, and pharmacodynamics of ZD1839 in SCCHN. Patients and Methods: Patients with recurrent or metastatic SCCHN were enrolled through the University of Chicago Phase II Consortium. Patients were allowed no more than one prior therapy for recurrent or metastatic disease and were treated with single-agent ZD1839 500 mg/d. Patient tumor biopsies were obtained and stained immunohistochemically for EGFR, extracellular signal-regulated kinase 1 (ERK1), and phosphorylated ERK1 (p-ERK). Study end points included response rate, time to progression, median survival, and inhibition of p-ERK. Results: Fifty-two patients were enrolled (40 male and 12 female) with a median age of 59 years (range, 34 to 84 years). Fourteen patients received ZD1839 through a feeding tube. Half the cohort received ZD1839 as second-line therapy. Forty-seven patients were assessable for response, with an observed response rate of 10.6% and a disease control rate of 53%. Median time to progression and survival were 3.4 and 8.1 months, respectively. The only grade 3 toxicity encountered was diarrhea in three patients. Performance status and development of skin toxicity were found to be strong predictors of response, progression, and survival. Ten biopsy samples were assessable and revealed no significant change in EGFR or p-ERK expression with ZD1839 therapy. Conclusion: ZD1839 has single-agent activity and is well tolerated in refractory SCCHN. In contrast to other reports, development of skin toxicity was a statistically significant predictor of response and improved outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Cohen, S., Carpenter, G., & King, L. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85573-4 · Cited by 858
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Forastiere, A. A., Metch, B., Schuller, D. E., Ensley, J. F., Hutchins, L. F., Triozzi, P., Kish, J. A., McClure, S., VonFeldt, E., & Williamson, S. K. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1245 · Cited by 752
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Jacobs, C., Lyman, G., Velez-García, E., Sridhar, K. S., Knight, W., Hochster, H., Goodnough, L. T., Mortimer, J. E., Einhorn, L. H., & Schacter, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.257 · Cited by 628
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Pérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,070
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Recent Advances in Head and Neck Cancer
Haddad, R. I., & Shin, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707975 · Cited by 916
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Self-citationPhase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 572
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.057 · Cited by 496
Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M. N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0913 · Cited by 492
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I. J., & Hung, M.-C. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.015 · Cited by 490
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Temam, S., Kawaguchi, H., El-Naggar, A. K., Jelinek, J., Tang, H., Liu, D. D., Lang, W., Issa, J.-P., Lee, J. J., & Mao, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6605 · Cited by 404
Herbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Self-citationGefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Optimal treatment for recurrent/metastatic head and neck cancer
Vermorken, J. B., & Specenier, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq453 · Cited by 383
Stewart, J. S. W., Cohen, E. E. W., Licitra, L., Van Herpen, C. M. L., Khorprasert, C., Soulieres, D., Vodvarka, P., Rischin, D., Garin, A. M., Hirsch, F. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0530 · Cited by 382
Self-citationDermatologic side effects associated with the epidermal growth factor receptor inhibitors
Agero, A. L. C., Dusza, S. W., Benvenuto-Andrade, C., Busam, K. J., Myskowski, P., & Halpern, A. C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.010 · Cited by 381
Mao, L., Hong, W. K., & Papadimitrakopoulou, V. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00090-x · Cited by 365
The molecular pathogenesis of head and neck squamous cell carcinoma
Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 363
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301
EGFR Targeting of Solid Tumors
Rocha-Lima, C. M., Soares, H. P., Raez, L. E., & Singal, R. (2007) · Cancer Control · doi:10.1177/107327480701400313 · Cited by 274
Cohen, E. E., Davis, D. W., Karrison, T. G., Seiwert, T. Y., Wong, S. J., Nattam, S., Kozloff, M. F., Clark, J. I., Yan, D.-H., Liu, W., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70002-6 · Cited by 273
Self-citationFrederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., & Raben, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0138 · Cited by 270
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J., Pulkkinen, J., Grenman, R., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 259
Colevas, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3348 · Cited by 257
Head and neck cancer: An evolving treatment paradigm
Cognetti, D. M., Weber, R. S., & Lai, S. Y. (2008) · Cancer · doi:10.1002/cncr.23654 · Cited by 253
Elser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2871 · Cited by 252
Acneiform eruptions associated with epidermal growth factor receptor–targeted chemotherapy
DeWitt, C. A., Siroy, A. E., & Stone, S. P. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.06.046 · Cited by 75
Zheng, J., Shen, L., Jiang, N., Zhu, Y., Wu, L., Cao, H., Sun, W., Zhou, J., & Zhou, J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.001 · Cited by 6
Metadata
- Authors
- Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-05-15
- Volume
- 21
- Issue
- 10
- Pages
- 1980-1987
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097584581
- Cited by
- 610
- References
- 18
- FWCI
- 78.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.